Goldman Sachs analyst Salveen Richter reinstates coverage on Relay Therapeutics (NASDAQ: RLAY) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage

Form 424B5 Relay Therapeutics, Inc. September 9, 2024 4:43 PM After-hours movers: Oracle, Rubrik, Relay Therapeutics September 9, 2024 4:39 PM Relay Therapeutics (RLAY) Announces $200M Proposed Public Offering of Common StockSeptember 9, 2024 4:34 PM Relay Therapeutics Announces Proposed Public Offering of Common StockSeptember 9, 2024 4:34 PM TD Cowen Out Positive on Relay Therapeutics (RLAY), Shares Up ~53%, 'we are constructive on Ph3 success based on today's data'September 9, 2024 3:20 PM Relay Therapeutics (RLAY) Shares Gain ~51%, PT Raised to $17 at BarclaysSeptember 9, 2024 3:03 PM Form 8-K Relay Therapeutics, Inc. For: Sep 09September 9, 2024 8:01 AM Relay Therapeutics (RLAY) Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free SurvivalSeptember 9, 2024 6:57 AM Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free SurvivalSeptember 9, 2024 6:55 AM Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024September 6, 2024 4:05 PM